Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
New York, NY
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Charlotte, NC
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Cincinnati, OH
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Tulsa, OK
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Lake Oswego, OR
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Hershey, PA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Pittsburg, PA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Pittsburg, PA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Dallas, TX
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Galveston, TX
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Galveston, TX
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Fairfax, VA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Spokane, WA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Tacoma, WA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
mi
from
Leuven,
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
mi
from
Leuven,
Click here to add this to my saved trials
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/18/2016
San Francisco General Hospital - Infectious Diseases
mi
from
San Francisco, CA
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/18/2016
San Francisco General Hospital - Infectious Diseases
mi
from
San Francisco, CA
Click here to add this to my saved trials
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/18/2016
Harbor UCLA Medical Center - Medicine - Infectious Diseases
mi
from
Torrance, CA
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/18/2016
Harbor UCLA Medical Center - Medicine - Infectious Diseases
mi
from
Torrance, CA
Click here to add this to my saved trials
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/18/2016
Morehouse School of Medicine - Morehouse Medical Associates - Atlanta
mi
from
Atlanta, GA
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/18/2016
Morehouse School of Medicine - Morehouse Medical Associates - Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/18/2016
The University of Chicago - Comer Children's Hospital - Infectious Diseases
mi
from
Chicago, IL
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/18/2016
The University of Chicago - Comer Children's Hospital - Infectious Diseases
mi
from
Chicago, IL
Click here to add this to my saved trials
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/18/2016
Washington University School of Medicine in St. Louis - Infectious Diseases
mi
from
Saint Louis, MO
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/18/2016
Washington University School of Medicine in St. Louis - Infectious Diseases
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/18/2016
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center
mi
from
Nashville, TN
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/18/2016
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Hamzavi Dermatology/Dermatology Specialists of Canton
mi
from
Canton, MI
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Hamzavi Dermatology/Dermatology Specialists of Canton
mi
from
Canton, MI
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Hamzavi Dermatology
mi
from
Fort Gratiot, MI
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Hamzavi Dermatology
mi
from
Fort Gratiot, MI
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Lynderm Research
mi
from
Markham,
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Lynderm Research
mi
from
Markham,
Click here to add this to my saved trials
Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
Evaluation of Sirolimus for the Treatment of the Autoimmune Blistering Dermatosis Pemphigus
Status: Enrolling
Updated:  2/24/2016
University of California, Irvine
mi
from
Irvine, CA
Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
Evaluation of Sirolimus for the Treatment of the Autoimmune Blistering Dermatosis Pemphigus
Status: Enrolling
Updated: 2/24/2016
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Honolulu, HI
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Louisville, KY
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Jackson, MS
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Austin, TX
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Anniston, AL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Anniston, AL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Birmingham, AL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Bentonville, AR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Bentonville, AR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Jonesboro, AR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Paragould, AR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Paragould, AR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Bakerfield, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Bakerfield, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Bell Gardens, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Bell Gardens, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Huntington Beach, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Long Beach, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Roseville, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Roseville, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Sacramento, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Colorado Springs, CO
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Washington,
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Atlantis, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Bay Pines, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Bay Pines, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Ft. Lauderdale, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Miami, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Pensacola, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
St. Petersburg, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Vero Beach, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
West Palm Beach, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials